Published in Ann Rheum Dis on July 19, 2013
Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. Croat Med J (2013) 1.40
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 1.31
High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int (2015) 1.02
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos (2016) 0.92
Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study. PLoS Med (2016) 0.92
The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis Res Ther (2014) 0.87
Giant cell arteritis: Current treatment and management. World J Clin Cases (2015) 0.84
Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am (2015) 0.78
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther (2015) 0.78
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int (2017) 0.77
Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int (2014) 0.77
Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int (2015) 0.77
The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. Arthritis Res Ther (2014) 0.77
Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore) (2015) 0.76
Prevention and treatment of bone changes associated with exposure to glucocorticoids. Curr Osteoporos Rep (2013) 0.76
Educational recommendations for the conduct, content and format of EULAR musculoskeletal ultrasound Teaching the Teachers Courses. RMD Open (2015) 0.75
Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int (2017) 0.75
Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One (2014) 0.75
Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study. Int J Rheumatol (2015) 0.75
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
Home monitoring of uterine activity. N Engl J Med (1992) 8.35
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol (1998) 7.43
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
Inhibition of Amazon deforestation and fire by parks and indigenous lands. Conserv Biol (2006) 6.36
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med (1995) 5.83
Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol (1986) 5.82
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis (2007) 3.89
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75
EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis (2007) 3.70
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
Making original data from clinical studies available for alternative analysis. J Rheumatol (1997) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
Social deprivation and prognostic benefits of cardiac surgery: observational study of 44 902 patients from five hospitals over 10 years. BMJ (2009) 2.95
Urgency and priority for cardiac surgery: a clinical judgment analysis. BMJ (1998) 2.90
Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'. Ann Rheum Dis (1983) 2.83
Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol (1998) 2.77
Radiographic assessment of the knee joint in osteoarthritis. Ann Rheum Dis (1992) 2.75
OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol (1993) 2.74
[Polymyalgia rheumatica and temporal arteritis]. Ned Tijdschr Geneeskd (2005) 2.68
The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford) (2006) 2.66
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol (1999) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Clinical judgment in rheumatoid arthritis. II. Judging 'current disease activity' in clinical practice. Ann Rheum Dis (1983) 2.44
Femoral nerve block for pain relief in hip fracture: a dose finding study. Anaesthesia (2014) 2.36
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
Signaling takes a breath--new quantitative perspectives on bioenergetics and signal transduction. Immunity (2001) 2.26
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Frequency and therapeutic implications of "skip metastases" in the neck from squamous carcinoma of the oral tongue. Head Neck (1997) 2.16
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol (1993) 2.14
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis (2004) 2.12
Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1996) 2.08
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Inability of rheumatologists to describe their true policies for assessing rheumatoid arthritis. Ann Rheum Dis (1986) 2.06
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis (2011) 2.04
Judging "current disease activity" in rheumatoid arthritis--an international comparison. J Rheumatol (1983) 2.01
Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol (2008) 1.99
Quality of life measures. Br J Rheumatol (1996) 1.97
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Minimal clinically important differences: review of methods. J Rheumatol (2001) 1.94
Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev (2007) 1.91
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis (2009) 1.90
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis (2007) 1.86
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology (2001) 1.85
Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum (2001) 1.84
Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum (2004) 1.83
Use of the McGrath videolaryngoscope in the management of difficult and failed tracheal intubation. Br J Anaesth (2007) 1.83
Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) (2002) 1.82
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis (2007) 1.73
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology (Oxford) (2005) 1.73
Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis. Ann Rheum Dis (2008) 1.73
Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis (2009) 1.72
The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol (2001) 1.69
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleukemias. Oncogene (1989) 1.65
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol (2001) 1.64
Smallest detectable difference in radiological progression. J Rheumatol (1999) 1.64
Time-resolved pump-probe experiments at the LCLS. Opt Express (2010) 1.61
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol (1998) 1.61
Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol (1995) 1.61
Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol (2003) 1.60